The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 307-316

  Habashy, Hany Onsy ^a,b   Rakha, Emad A ^a   Ellis, Ian O ^a   Powe, Desmond G ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MANSOURA UNIVERSITY   (Egypt)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Breast carcinoma; CARM1; Coactivators; Immunohistochemistry; Oestrogen receptor; Prognosis

Indexed keywords

CARM1 PROTEIN; CD71 ANTIGEN; CYCLIN E; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; NUCLEAR RECEPTOR COACTIVATOR; PROTEIN P53; STEROID RECEPTOR; THYMIDINE KINASE 1; UNCLASSIFIED DRUG; COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1; PROTEIN ARGININE METHYLTRANSFERASE; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEIN-ARGININE N-METHYLTRANSFERASES; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84881480077     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2614-y     Document Type: Article

References (28)

1. Leo C, Chen JD (2000) The SRC family of nuclear receptor coactivators. Gene 245(1):1-11
2. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai M-J, Edwards DP, et al. (1998) The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273(20):12101-12108
3. Miao F, Li S, Chavez V, Lanting L, Natarajan R (2006) Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-{kappa}B-mediated gene transcription through methylation of histone H3 at Arginine 17. Mol Endocrinol 20(7):1562-1573
4. Schurter BT, Koh SS, Chen D, Bunick GJ, Harp JM, Hanson BL, et al. (2001) Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. Biochemistry 40(19):5747-5756
5. Stallcup MR, Kim JH, Teyssier C, Lee Y-H, Ma H, Chen D (2003) The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J Steroid Biochem Mol Biol 85(2-5):139-145
6. Frietze S, Lupien M, Silver PA, Brown M (2008) CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res 68(1):301-306
7. An W, Kim J, Roeder RG (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117(6):735-748
8. Covic M, Hassa PO, Saccani S, Buerki C, Meier NI, Lombardi C, et al. (2005) Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappa B-dependent gene expression. EMBO J 24(1):85-96
9. Hong H, Kao C, Jeng M-H, Eble JN, Koch MO, Gardner TA, et al. (2004) Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 101(1):83-89
10. El-Rehim DMA, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR, et al. (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340-350
11. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast-cancer.1. The value of histological grade in breast-cancer-experience from a large study with long-term follow-up. Histopathology 19(5):403-410
12. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast-cancer. Breast Cancer Res Treat 22(3):207-219
13. Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, et al. (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44(11):1541-1551
14. McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS (1985) Estrogen-receptor analyses-correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716-721
15. Habashy H, Powe D, Rakha E, Ball G, Macmillan R, Green A, et al. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 120(3):603-612
16. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252-7259
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235
18. El-Rehim DMA, Pinder SE, Paish CE, Bell J, Blamey R, Robertson JFR, et al. (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661-671
19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
20. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18):10393-10398
21. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, et al. (2006) Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5(11):2914-2918
22. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98(19):10869-10874
23. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418-8423
24. Ahr A, Holtrich U, Solbach C, Scharl A, Strebhardt K, Karn T, et al. (2001) Gene expression profiling for molecular identification of high-risk breast cancer patients. Geburtshilfe Frauenheilkd 61(12):954-963
25. Mann M, Cortez V, Vadlamudi R (2013) PELP1 oncogenic functions involve CARM1 regulation. Carcinogenesis
26. El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng DH, et al. (2006) Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci USA 103(36):13351-13356
27. Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353(16):1652-1654
28. Davis MB, Liu X, Wang S, Reeves J, Khramtsov A, Huo D, Olopade OI (2013) Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer 12(1):40